Reviews Gadopentetate Dimeglumine


No reviews yet.

Magnevist Drug Description
MAGNEVIST®
(gadopentetate dimeglumine) Injection
FOR INTRAVENOUS ADMINISTRATION

WARNING: NEPHROGENIC SYSTEMIC FIBROSIS
Gadolinium-based contrast agents increase the risk for nephrogenic systemic
fibrosis (NSF) in patients with:

Acute or chronic severe renal insufficiency (glomerular filtration rate
< 30 mL/min/1.73m2), or
Acute renal insufficiency of any severity due to the hepato-renal syndrome
or in the perioperative liver transplantation period.

In these patients, avoid use of gadolinium-based contrast agents unless the
diagnostic information is essential and not available with non-contrast enhanced
magnetic resonance imaging (MRI). NSF may result in fatal or debilitating systemic
fibrosis affecting the skin, muscle and internal organs. Screen all patients
for renal dysfunction by obtaining a history and/or laboratory tests. When administering
a gadolinium-based contrast agent, do not exceed the recommended dose and allow
a sufficient period of time for elimination of the agent from the body prior
to any readminstration (See WARNINGS).

DRUG DESCRIPTION



What are the possible side effects of gadopentetate dimeglumine (Magnevist)?

Some of the side effects of gadopentetate dimeglumine can occur up to 24 hours after you have received the medication.
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

seizure (convulsions);
urinating more or less than usual, or not at all;
feeling light-headed,...
Read All Potential Side Effects for Magnevist »




MAGNEVIST ® (brand of gadopentetate dimeglumine) Injection is the N- methylglucamine
salt of the gadolinium complex of diethylenetriamine pentaacetic acid, and is
an injectable contrast medium for magnetic resonance imaging (MRI).
MAGNEVIST Injection is provided as a sterile, clear, colorless to slightly
yellow aqueous solution for intravenous injection.
MAGNEVIST Injection is a 0.5-mol/L solution of 1-deoxy-1-(methylamino)-D-glucitol
dihydrogen [N,N-bis[2-[bis(carboxymethyl)amino]ethyl]-glycinato-(5--)-]gadolinate(2-)(2:1)
with a molecular weight of 938, an empirical formula of C28H54GdN5O20,
and has the following structural formula:








Each mL of MAGNEVIST Injection contains 469.01 mg gadopentetate dimeglumine, 0.99 mg meglumine, 0.40 mg diethylenetriamine pentaacetic acid and water for injection. MAGNEVIST Injection contains no antimicrobial preservative.
MAGNEVIST Injection has a pH of 6.5 to 8.0. Pertinent physicochemical data
are noted below: PARAMETER Osmolality (mOsmol/ kg water) at 37° C 1,960
Viscosity (CP) at 20° C 4.9 at 37° C 2.9 Density (g/mL) at 25° C
1.195 Specific gravity at 25° C 1.208 Octanol: H2O at 25°
C and pH7 log Pow = - 5.4
MAGNEVIST Injection has an osmolality 6.9 times that of plasma which has an osmolality of 285 mOsmol/ kg water. MAGNEVIST Injection is hypertonic under conditions of use.
Last reviewed on RxList: 6/16/2009




Magnevist Drug Description
MAGNEVIST®
(gadopentetate dimeglumine) Injection
FOR INTRAVENOUS ADMINISTRATION

WARNING: NEPHROGENIC SYSTEMIC FIBROSIS
Gadolinium-based contrast agents increase the risk for nephrogenic systemic
fibrosis (NSF) in patients with:

Acute or chronic severe renal insufficiency (glomerular filtration rate
< 30 mL/min/1.73m2), or
Acute renal insufficiency of any severity due to the hepato-renal syndrome
or in the perioperative liver transplantation period.

In these patients, avoid use of gadolinium-based contrast agents unless the
diagnostic information is essential and not available with non-contrast enhanced
magnetic resonance imaging (MRI). NSF may result in fatal or debilitating systemic
fibrosis affecting the skin, muscle and internal organs. Screen all patients
for renal dysfunction by obtaining a history and/or laboratory tests. When administering
a gadolinium-based contrast agent, do not exceed the recommended dose and allow
a sufficient period of time for elimination of the agent from the body prior
to any readminstration (See WARNINGS).

DRUG DESCRIPTION



What are the possible side effects of gadopentetate dimeglumine (Magnevist)?

Some of the side effects of gadopentetate dimeglumine can occur up to 24 hours after you have received the medication.
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

seizure (convulsions);
urinating more or less than usual, or not at all;
feeling light-headed,...
Read All Potential Side Effects for Magnevist »




MAGNEVIST ® (brand of gadopentetate dimeglumine) Injection is the N- methylglucamine
salt of the gadolinium complex of diethylenetriamine pentaacetic acid, and is
an injectable contrast medium for magnetic resonance imaging (MRI).
MAGNEVIST Injection is provided as a sterile, clear, colorless to slightly
yellow aqueous solution for intravenous injection.
MAGNEVIST Injection is a 0.5-mol/L solution of 1-deoxy-1-(methylamino)-D-glucitol
dihydrogen [N,N-bis[2-[bis(carboxymethyl)amino]ethyl]-glycinato-(5--)-]gadolinate(2-)(2:1)
with a molecular weight of 938, an empirical formula of C28H54GdN5O20,
and has the following structural formula:








Each mL of MAGNEVIST Injection contains 469.01 mg gadopentetate dimeglumine, 0.99 mg meglumine, 0.40 mg diethylenetriamine pentaacetic acid and water for injection. MAGNEVIST Injection contains no antimicrobial preservative.
MAGNEVIST Injection has a pH of 6.5 to 8.0. Pertinent physicochemical data
are noted below: PARAMETER Osmolality (mOsmol/ kg water) at 37° C 1,960
Viscosity (CP) at 20° C 4.9 at 37° C 2.9 Density (g/mL) at 25° C
1.195 Specific gravity at 25° C 1.208 Octanol: H2O at 25°
C and pH7 log Pow = - 5.4
MAGNEVIST Injection has an osmolality 6.9 times that of plasma which has an osmolality of 285 mOsmol/ kg water. MAGNEVIST Injection is hypertonic under conditions of use.
Last reviewed on RxList: 6/16/2009




Magnevist Drug Description
MAGNEVIST®
(gadopentetate dimeglumine) Injection
FOR INTRAVENOUS ADMINISTRATION

WARNING: NEPHROGENIC SYSTEMIC FIBROSIS
Gadolinium-based contrast agents increase the risk for nephrogenic systemic
fibrosis (NSF) in patients with:

Acute or chronic severe renal insufficiency (glomerular filtration rate
< 30 mL/min/1.73m2), or
Acute renal insufficiency of any severity due to the hepato-renal syndrome
or in the perioperative liver transplantation period.

In these patients, avoid use of gadolinium-based contrast agents unless the
diagnostic information is essential and not available with non-contrast enhanced
magnetic resonance imaging (MRI). NSF may result in fatal or debilitating systemic
fibrosis affecting the skin, muscle and internal organs. Screen all patients
for renal dysfunction by obtaining a history and/or laboratory tests. When administering
a gadolinium-based contrast agent, do not exceed the recommended dose and allow
a sufficient period of time for elimination of the agent from the body prior
to any readminstration (See WARNINGS).

DRUG DESCRIPTION



What are the possible side effects of gadopentetate dimeglumine (Magnevist)?

Some of the side effects of gadopentetate dimeglumine can occur up to 24 hours after you have received the medication.
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

seizure (convulsions);
urinating more or less than usual, or not at all;
feeling light-headed,...
Read All Potential Side Effects for Magnevist »




MAGNEVIST ® (brand of gadopentetate dimeglumine) Injection is the N- methylglucamine
salt of the gadolinium complex of diethylenetriamine pentaacetic acid, and is
an injectable contrast medium for magnetic resonance imaging (MRI).
MAGNEVIST Injection is provided as a sterile, clear, colorless to slightly
yellow aqueous solution for intravenous injection.
MAGNEVIST Injection is a 0.5-mol/L solution of 1-deoxy-1-(methylamino)-D-glucitol
dihydrogen [N,N-bis[2-[bis(carboxymethyl)amino]ethyl]-glycinato-(5--)-]gadolinate(2-)(2:1)
with a molecular weight of 938, an empirical formula of C28H54GdN5O20,
and has the following structural formula:








Each mL of MAGNEVIST Injection contains 469.01 mg gadopentetate dimeglumine, 0.99 mg meglumine, 0.40 mg diethylenetriamine pentaacetic acid and water for injection. MAGNEVIST Injection contains no antimicrobial preservative.
MAGNEVIST Injection has a pH of 6.5 to 8.0. Pertinent physicochemical data
are noted below: PARAMETER Osmolality (mOsmol/ kg water) at 37° C 1,960
Viscosity (CP) at 20° C 4.9 at 37° C 2.9 Density (g/mL) at 25° C
1.195 Specific gravity at 25° C 1.208 Octanol: H2O at 25°
C and pH7 log Pow = - 5.4
MAGNEVIST Injection has an osmolality 6.9 times that of plasma which has an osmolality of 285 mOsmol/ kg water. MAGNEVIST Injection is hypertonic under conditions of use.
Last reviewed on RxList: 6/16/2009




Magnevist Drug Description
MAGNEVIST®
(gadopentetate dimeglumine) Injection
FOR INTRAVENOUS ADMINISTRATION

WARNING: NEPHROGENIC SYSTEMIC FIBROSIS
Gadolinium-based contrast agents increase the risk for nephrogenic systemic
fibrosis (NSF) in patients with:

Acute or chronic severe renal insufficiency (glomerular filtration rate
< 30 mL/min/1.73m2), or
Acute renal insufficiency of any severity due to the hepato-renal syndrome
or in the perioperative liver transplantation period.

In these patients, avoid use of gadolinium-based contrast agents unless the
diagnostic information is essential and not available with non-contrast enhanced
magnetic resonance imaging (MRI). NSF may result in fatal or debilitating systemic
fibrosis affecting the skin, muscle and internal organs. Screen all patients
for renal dysfunction by obtaining a history and/or laboratory tests. When administering
a gadolinium-based contrast agent, do not exceed the recommended dose and allow
a sufficient period of time for elimination of the agent from the body prior
to any readminstration (See WARNINGS).

DRUG DESCRIPTION



What are the possible side effects of gadopentetate dimeglumine (Magnevist)?

Some of the side effects of gadopentetate dimeglumine can occur up to 24 hours after you have received the medication.
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

seizure (convulsions);
urinating more or less than usual, or not at all;
feeling light-headed,...
Read All Potential Side Effects for Magnevist »




MAGNEVIST ® (brand of gadopentetate dimeglumine) Injection is the N- methylglucamine
salt of the gadolinium complex of diethylenetriamine pentaacetic acid, and is
an injectable contrast medium for magnetic resonance imaging (MRI).
MAGNEVIST Injection is provided as a sterile, clear, colorless to slightly
yellow aqueous solution for intravenous injection.
MAGNEVIST Injection is a 0.5-mol/L solution of 1-deoxy-1-(methylamino)-D-glucitol
dihydrogen [N,N-bis[2-[bis(carboxymethyl)amino]ethyl]-glycinato-(5--)-]gadolinate(2-)(2:1)
with a molecular weight of 938, an empirical formula of C28H54GdN5O20,
and has the following structural formula:








Each mL of MAGNEVIST Injection contains 469.01 mg gadopentetate dimeglumine, 0.99 mg meglumine, 0.40 mg diethylenetriamine pentaacetic acid and water for injection. MAGNEVIST Injection contains no antimicrobial preservative.
MAGNEVIST Injection has a pH of 6.5 to 8.0. Pertinent physicochemical data
are noted below: PARAMETER Osmolality (mOsmol/ kg water) at 37° C 1,960
Viscosity (CP) at 20° C 4.9 at 37° C 2.9 Density (g/mL) at 25° C
1.195 Specific gravity at 25° C 1.208 Octanol: H2O at 25°
C and pH7 log Pow = - 5.4
MAGNEVIST Injection has an osmolality 6.9 times that of plasma which has an osmolality of 285 mOsmol/ kg water. MAGNEVIST Injection is hypertonic under conditions of use.
Last reviewed on RxList: 6/16/2009




Magnevist Drug Description
MAGNEVIST®
(gadopentetate dimeglumine) Injection
FOR INTRAVENOUS ADMINISTRATION

WARNING: NEPHROGENIC SYSTEMIC FIBROSIS
Gadolinium-based contrast agents increase the risk for nephrogenic systemic
fibrosis (NSF) in patients with:

Acute or chronic severe renal insufficiency (glomerular filtration rate
< 30 mL/min/1.73m2), or
Acute renal insufficiency of any severity due to the hepato-renal syndrome
or in the perioperative liver transplantation period.

In these patients, avoid use of gadolinium-based contrast agents unless the
diagnostic information is essential and not available with non-contrast enhanced
magnetic resonance imaging (MRI). NSF may result in fatal or debilitating systemic
fibrosis affecting the skin, muscle and internal organs. Screen all patients
for renal dysfunction by obtaining a history and/or laboratory tests. When administering
a gadolinium-based contrast agent, do not exceed the recommended dose and allow
a sufficient period of time for elimination of the agent from the body prior
to any readminstration (See WARNINGS).

DRUG DESCRIPTION



What are the possible side effects of gadopentetate dimeglumine (Magnevist)?

Some of the side effects of gadopentetate dimeglumine can occur up to 24 hours after you have received the medication.
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

seizure (convulsions);
urinating more or less than usual, or not at all;
feeling light-headed,...
Read All Potential Side Effects for Magnevist »




MAGNEVIST ® (brand of gadopentetate dimeglumine) Injection is the N- methylglucamine
salt of the gadolinium complex of diethylenetriamine pentaacetic acid, and is
an injectable contrast medium for magnetic resonance imaging (MRI).
MAGNEVIST Injection is provided as a sterile, clear, colorless to slightly
yellow aqueous solution for intravenous injection.
MAGNEVIST Injection is a 0.5-mol/L solution of 1-deoxy-1-(methylamino)-D-glucitol
dihydrogen [N,N-bis[2-[bis(carboxymethyl)amino]ethyl]-glycinato-(5--)-]gadolinate(2-)(2:1)
with a molecular weight of 938, an empirical formula of C28H54GdN5O20,
and has the following structural formula:








Each mL of MAGNEVIST Injection contains 469.01 mg gadopentetate dimeglumine, 0.99 mg meglumine, 0.40 mg diethylenetriamine pentaacetic acid and water for injection. MAGNEVIST Injection contains no antimicrobial preservative.
MAGNEVIST Injection has a pH of 6.5 to 8.0. Pertinent physicochemical data
are noted below: PARAMETER Osmolality (mOsmol/ kg water) at 37° C 1,960
Viscosity (CP) at 20° C 4.9 at 37° C 2.9 Density (g/mL) at 25° C
1.195 Specific gravity at 25° C 1.208 Octanol: H2O at 25°
C and pH7 log Pow = - 5.4
MAGNEVIST Injection has an osmolality 6.9 times that of plasma which has an osmolality of 285 mOsmol/ kg water. MAGNEVIST Injection is hypertonic under conditions of use.
Last reviewed on RxList: 6/16/2009





Other reviews about Gadopentetate Dimeglumine on wordpress

What is Pancreatic Neoplasms
  by planetultramarathon
link Pancreas, Mucinous Cystic Neoplasm Last Updated: February 21, 2007 Email to a Colleague Synonyms and related keywords: MCN, macrocystic cystadenoma, cystadenocarcinoma, mucinous duct ectasia, mucinous ductal ectasia, papillary adenocarcinoma, […]


Acute and non acute Schmorl's nodes,disc vascularization : MR findings & recent concepts
  by das himadri
  Disc degeneration itself is a normal process in the elderly, beginning as early in the twenties. There are 3 complications of degenerative disease of the spinal column, making the normal […]


What is Gadolinium?
  by gadolinium
Gadolinium is a chemical used for magnetic resonance imaging (MRI) which helps provide greater contrast between normal tissue and abnormal tissue in the brain and body. The U.S. […]


multiple myeloma & mri
  by turbospinecho
Multiple myeloma (MM) is an incurable clonal B-cell malignancy with terminally differentiated plasma cells. It afflicts approximately 55,000 people in the United States. Over the past 5 years, […]


Online case record....Benign subependymal nodules
  by Yasser Metwally
The author: Professor Yasser Metwally http://yassermetwally.com INTRODUCTION December 29, 2008 — Patient is a 45-year-old male status-post total thyroidectomy. The patient presented with worsening of memory and cognitive problems. There is […]


Aneurysmal bone cysts (ABCs)
  by Yasser Metwally
The author: Professor Yasser Metwally http://yassermetwally.com INTRODUCTION December 9, 2009 — Aneurysmal bone cysts (ABCs) typically affect young patients, with […]


Nephrogenic Systemic Fibrosis
  by Ameliana Kamaludin
1/4/2010 Nephrogenic systemic fibrosis (NSF) was first described in 2000 as a scleromyxedema-like illness that presented with cutaneous fibrosis in 14 patients receiving chronic hemodialysis (Cowper et al, 2000). […]


1. Bones
  by blackbookofradiology
Click this Link to Search Radiology Articles and Images as well as General Medical Information Accessory Ossicles and Sesamoid Bones: Spectrum of Pathology and Imaging Evaluation http://www.appliedradiology.com/Article.aspx?id=13698 Babak N. Kalantari, MD […]


3. Muscle
  by tmyersnrscmo
Click this Link to Search Radiology Articles and Images as well as General Medical Information Abnormal Signal Intensity in Skeletal Muscle at MR Imaging: Patterns, Pearls, and Pitfalls http://radiographics.rsna.org/content/20/suppl_1/S295.full David A. […]


MRI Contrast Agents to Avoid
  by theresma
http://www.auntminnie.com/index.asp?Sec=sup&Sub=mri&Pag=dis&ItemId=91014&wf=3772ACR tackles NSF risk in new gadolinium MRI contrast guidance By James Brice AuntMinnie.com contributing writerJune 17, 2010The American College of Radiology (ACR) of Reston, VA, is […]



Other reviews about Gadopentetate Dimeglumine on web:

Gadopentetic acid (in the form of gadopentetate dimeglumine or Gd-DTPA) is the first paramagnetic magnetic resonance imaging (MRI) contrast agent. Gadopentetic acid - Wikipedia, the free encyclopedia


Learn about the prescription medication Magnevist (Gadopentetate Dimeglumine), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Magnevist (Gadopentetate Dimeglumine) Drug Information: Uses, Side ...


All about Gadopentetate Dimeglumine. View complete and up to date Gadopentetate Dimeglumine information - part of the Drugs.com trusted medication database. Gadopentetate Dimeglumine Facts and Comparisons at Drugs.com


This page contains information, links to basics and news resources about Gadopentetate Dimeglumine, furthermore the related entries: Magnevist, Contrast Agents, Ionic Intravenous ... Magnetic Resonance TIP - MRI Database : Gadopentetate Dimeglumine


Gadopentetate Brand names: Magnevist®Multihance® Chemical formula: Gadopentetate dimeglumine injection What is Gadopentetate dimeglumine Gadopentetate: Information from Answers.com


gadopentetate dimeglumine /gad·o·pen·te·tate di·meg·lu·mine/ (gad″o-pen´tĕ-tāt di-meg´loo-mēn) a paramagnetic agent used as a contrast agent in magnetic resonance ... gadopentetate dimeglumine - definition of gadopentetate ...


Version: 2.5: Creation Date: 2005-06-13 13:24:05: Update Date: 2009-06-23 18:08:20: Primary Accession Number: DB00789: Secondary Accession Number: APRD00991; Name DrugBank: Showing Gadopentetate dimeglumine (DB00789)


Gadopentetate Dimeglumine Drug Information from Drugs.com. Includes Gadopentetate Dimeglumine side effects, interactions and indications. Gadopentetate Dimeglumine Drug Information, Professional


What is the most important information I should know about gadopentetate dimeglumine? What is gadopentetate dimeglumine? What should I discuss with my health care provider before ... CIGNA - gadopentetate dimeglumine


The information on this page is seed content provided by an organization. Please help improve this Article by adding to it. If you are a physician or PhD, learn how to edit. If you ... Clinical:Magnevist (gadopentetate dimeglumine) - Medpedia





Featured Reviews

Reviews George Butunoiu

I know George Butunoiu for more than 4 years now. We have worked on various projects, we have launched a joined site "registrul aberatiilor", we ate together several times, I consulted him on several emarketing matters... He is a great guy....
Read More  |  Review This
Reviews Niferex-150

Niferex-150 Drug Description Niferex ® -150 Capsules (ferrous asparto glycinate and polysaccharide iron) Complex DRUG DESCRIPTION Supplement Facts Serving Size 1 Capsule   Amount Per Serving % Daily Value ...
Read More  |  Review This
Reviews Desogestrel Ethinyl Estradiol Tablets

Cyclessa Drug Description Cyclessa® (desogestrel/ethinyl estradiol tablets) Patients should be counseled that this product does not protect against HIV infection (AIDS) and other sexually transmitted diseases. DRUG DESCRIPTION What...
Read More  |  Review This
Reviews Levo Dromoran

Levo Dromoran Drug Description LEVO-DROMORAN (levorphanol tartrate) Injection, Solution and Tablet DRUG DESCRIPTION What are the possible side effects of levorphanol (Levo-Dromoran)? Get emergency medical help if you have any of...
Read More  |  Review This
Reviews Monopril HCT

Monopril HCT Drug Description MONOPRIL®-HCT 10/12.5 MONOPRIL®-HCT 20/12.5 (fosinopril sodium-hydrochlorothiazide) Tablets USE IN PREGNANCY When used in pregnancy during the second and third trimesters, ACE inhibitors can...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....